REVAHALE, India’s first once-daily nebulised LAMA for COPD REVAHALE
Zydus Lifesciences Limited, (including its subsidiaries and affiliates), an innovation-driven global lifesciences company, launched on August 10 REVAHALE™ (Revefenacin), India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD)
REVAHALETM is the first and only LAMA available in India that combines once-daily dosing with nebulised administration, offering a new treatment option for COPD patients who require nebulised therapy.
Designed to provide sustained 24-hour bronchodilation with a single daily dose, REVAHALETM addresses important challenges associated with inhaler-dependent therapies, particularly among elderly patients and those with severe respiratory impairment.
COPD remains a significant public health challenge in India and is a leading cause of morbidity and mortality. It is driven heavily by severe outdoor air pollution, indoor biomass fuel smoke, and tobacco use. The country accounts for a massive share of global COPD mortality, yet the condition remains widely underdiagnosed due to limited access to routine spirometry testing
Key Risk Factors
• Air Pollution: High ambient particulate matter in urban centers alongside rural indoor exposure to wood or dung smoke.
• Smoking: Active tobacco smoking and exposure to secondhand smoke.
• Demographics: Higher vulnerability among older adults aged 60 and above
Regional and Group Disparities
• Geography: North India shows a higher recorded prevalence compared to Western regions.
• Gender: Higher diagnosis rates appear among males, though non-smoking women suffer disproportionately from indoor biomass fuels.
• Setting: Hospital data reveals higher severity concentrations than general community samples
While inhaled bronchodilator therapies have transformed disease management, many patients continue to experience difficulties using handheld inhalers, cognitive limitations, severe breathlessness, or an inability to generate sufficient inspiratory effort for effective drug delivery.
REVAHALETM has been developed to address these unmet needs through a convenient nebulised delivery platform that reduces dependence on inhalation technique and inspiratory flow.
The therapy is compatible with standard jet nebulisers, providing flexibility and ease of use for patients and caregivers.
Revefenacin is designed to deliver sustained bronchodilation over 24 hours through once-daily administration.
Clinical studies have demonstrated significant and sustained improvements in lung function in patients with moderate to very severe COPD, while maintaining a favourable safety profile. Its lung-selective design is intended to maximise bronchodilatory effects in the airways while minimising systemic exposure.
By combining once-daily administration, compatibility with standard jet nebulisers and sustained 24-hour bronchodilation, REVAHALETM is said to offer a differentiated maintenance treatment option in COPD care.
Please note that Zydus Life Sciences Limited claims to be an organisation that empowers people to live healthier and more fulfilled lives. It says it is an innovative global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group employs over 30,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives.
The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities
